Author

M. E. McGrath

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 4 Organism:mouse· 4 Research Focus:cell signaling & trafficking· 1 Research Focus:development & morphogenesis· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Research Focus:metabolism & bioenergetics· 1

Frequent Co-Authors

C. Dillen· 4 shared D. J. Dowling· 3 shared E. Nanishi· 3 shared H.-S. Seo· 3 shared M. Frieman· 3 shared O. Levy· 3 shared R. K. Ernst· 3 shared S. Dhe-Paganon· 3 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

C. Dillen

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

SARS-CoV-2 ORF8 modulates lung inflammation and clinical disease progression

M. Frieman, M. E. McGrath, Y. Xue, L. Taylor, C. Dillen, J. Ardanuy, N. Gonzalez-Juarbe, L. Baracco, R. Kim, R. Hart, N. Assad-Garcia, S. Vashee

This study shows that SARS-CoV-2 ORF8 protein modulates lung inflammation and disease severity in mice by affecting macrophage infiltration and function.

bioRxiv · Sep 8, 2023Microbiology

Reduced SARS-CoV-2 mRNA vaccine immunogenicity and protection in mice with diet-induced obesity and insulin resistance.

T. R. O'Meara, E. Nanishi, M. E. McGrath, S. Barman, D. Dong, C. Dillen, M. Menon, H.-S. Seo, S. Dhe-Paganon, R. K. Ernst, O. Levy, M. B. Frieman, D. J. Dowling

bioRxiv · Dec 7, 2022Immunology

An adjuvanted SARS-CoV-2 RBD nanoparticle elicits neutralizing antibodies and fully protective immunity in aged mice

F. Borriello, E. Nanishi, H.-S. Seo, T. R. OMeara, M. E. McGrath, Y. Saito, R. E. Haupt, J. Chen, J. Diray-Arce, K. Song, A. Z. Xu, T. M. Caradonna, J. Feldman, B. M. Hauser, A. G. Schmidt, , O. Levy

This study identifies an adjuvanted SARS-CoV-2 RBD nanoparticle that induces neutralizing antibodies and full protection in aged mice.

bioRxiv · Sep 9, 2021 · PreprintImmunology

Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity

E. Nanishi, F. Borriello, T. R. O'Meara, M. E. McGrath, Y. Saito, R. E. Haupt, H.-S. Seo, S. D. van Haren, B. Brook, J. Chen, J. Diray-Arce, S. Doss-Gollin, M. De Leon, K. Chew, M. Menon, , D. J. Dowling

This study evaluates AH:CpG adjuvant's ability to enhance RBD vaccine efficacy in aged mice and human elder cells, showing strong neutralizing antibody responses and cytokine production.

bioRxiv · May 20, 2021Immunology

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19

B. Boras, R. M. Jones, B. J. Anson, D. Arenson, L. Aschenbrenner, M. A. Bakowski, N. Beutler, J. Binder, E. Chen, H. Eng, J. Hammond, R. Hoffman, E. P. Kadar, R. Kania, E. Kimoto, , M. E. McGrath

This study identifies PF-00835321 as a potent inhibitor of SARS-CoV-2 3CL protease with in vitro antiviral activity and clinical evaluation potential.

bioRxiv · Sep 12, 2020 · PreprintPharmacology & Toxicology